Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies

被引：0
作者：
V. Moreno
E. Calvo
M. R. Middleton
F. Barlesi
C. Gaudy-Marqueste
A. Italiano
E. Romano
A. Marabelle
E. Chartash
K. Dobrenkov
H. Zhou
E. C. Connors
Y. Zhang
M. Wermke
机构：
[1] START Madrid-FJD,START Madrid
[2] Hospital Fundación Jimenez Diaz,CIOCC
[3] Centro Integral Oncológico Clara Campal,Department of Oncology
[4] University of Oxford,CEPCM CLIP2, Assistance Publique Hôpitaux de Marseille
[5] Aix Marseille University,Department of Medical Oncology
[6] University of Bordeaux,Early Phase Trials Unit
[7] Institut Bergonié,Center for Cancer Immunotherapy, Dept of Oncology, INSERM U932
[8] PSL Research University,Medical Oncology Department
[9] Institut Curie,undefined
[10] Gustave Roussy,undefined
[11] Merck & Co.,undefined
[12] Inc.,undefined
[13] Technische Universität Dresden,undefined
[14] Medizinische Fakultät,undefined
[15] NCT/UCC Early Clinical Trial Unit,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
RIG-I; Interferon type I; Innate immunity; Intratumoral injection; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2985 / 2998
页数：13
相关论文
共 195 条
[1]  
Fan CA(2018)Review of immune therapies targeting ovarian cancer Curr Treat Options Oncol 19 74-45
[2]  
Reader J(2020)Perspectives on treatment of metastatic colorectal cancer with immune checkpoint inhibitor therapy Oncologist 25 33-1874
[3]  
Roque DM(2021)Targeting innate immunity in cancer therapy Vaccines (Basel) 9 138-121
[4]  
Morse MA(2016)The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition Clin Cancer Res 22 1865-6195
[5]  
Hochster H(2015)RIG-I in RNA virus recognition Virology 479–480 110-414
[6]  
Benson A(2018)Therapeutically active RIG-I agonist induces immunogenic tumor cell killing in breast cancers Cancer Res 78 6183-2411
[7]  
Rameshbabu S(2015)Type I interferons in anticancer immunity Nat Rev Immunol 15 405-2339
[8]  
Labadie BW(2009)Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells J Clin Invest 119 2399-1791
[9]  
Argulian A(2019)Activation of RIG-I signaling to increase the pro-inflammatory phenotype of a tumor Oncotarget 10 2338-e152
[10]  
Patnaik A(2017)Selective stimulation of RIG-I with a novel synthetic RNA induces strong anti-tumor immunity in mouse tumor models (abstract) Cancer Immunol Res 5 B44-247
12345678910